Table 3. Antimicrobial susceptibilities of Pseudomonas aeruginosa clinical isolates.

	No. of isolates (%)
	Carbapenem-susceptible (n = 229)			Carbapenem-non-susceptible (n = 100)			Total (n = 329)
	Susceptible	Intermediate	Resistant	Susceptible	Intermediate	Resistant	Susceptible	Intermediate	Resistant
Amoxicillin-clavulanate	0 (0)	0 (0)	229 (100)	0 (0)	0 (0)	100 (100)	0 (0)	0 (0)	329 (100)
Piperacillin-tazobactam	215 (93.9)	0 (0)	14 (6.1)	51 (51)	2 (2)	47 (47)	266 (80.9)	2 (0.6)	61 (18.5)
Ticarcillin-clavulanate	208 (90.8)	0 (0)	21 (9.2)	45 (45)	0 (0)	55 (55)	253 (76.9)	0 (0)	76 (23.1)
Aztreonam	174 (76.0)	24 (10.5)	31 (13.5)	23 (23)	23 (23)	54 (54)	197 (59.9)	47 (14.3)	85 (25.8)
Ceftazidime	193 (84.3)	15 (6.5)	21 (9.2)	37 (37)	11 (11)	52 (52)	230 (69.9)	26 (7.9)	73 (22.2)
Cefepime	194 (84.7)	26 (11.4)	9 (3.9)	32 (32)	17 (17)	51 (51)	226 (68.7)	43 (13.1)	60 (18.2)
Imipenem	229 (100)	0 (0)	0 (0)	1 (1)	5 (5)	94 (94)	230 (69.9)	5 (1.5)	94 (28.6)
Meropenem	229 (100)	0 (0)	0 (0)	7 (7)	17 (17)	76 (76)	236 (71.7)	17 (5.2)	76 (23.1)
Amikacin	222 (97.0)	1 (0.4)	6 (2.6)	63 (63)	1 (1)	36 (36)	285 (86.6)	2 (0.6)	42 (12.8)
Gentamicin	209 (91.2)	6 (2.7)	14 (6.1)	57 (57)	1 (1)	42 (42)	266 (80.9)	7 (2.1)	56 (17.0)
Tobramycin	211 (92.1)	2 (0.9)	16 (7.0)	55 (55)	2 (2)	43 (43)	266 (80.9)	4 (1.2)	59 (17.9)
Trimethoprim-sulfamethoxazole	0 (0)	0 (0)	229 (100)	0 (0)	0 (0)	100 (100)	0 (0)	0 (0)	329 (100)
Ciprofloxacin	186 (81.2)	5 (2.2)	38 (16.6)	20 (20)	5 (5)	75 (75)	206 (62.6)	10 (3.1)	113 (34.3)
Tetracycline	2 (0.9)	0 (0)	227 (99.1)	1 (1)	2 (2)	97 (97)	3 (0.9)	2 (0.6)	324 (98.5)
Colistin	229 (100)	0 (0)	0 (0)	100 (100)	0 (0)	0 (0)	329 (100)	0 (0)	0 (0)